instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'CLINDAMYCIN'? | Very Elevated IgE, Atopy, and Severe Infection: A Genomics-Based Diagnostic Approach to a Spectrum of Diseases.
Elevated IgE has been long recognized as an important clinical marker of atopy but can be seen in a myriad of conditions. The discovery of autosomal dominant STAT3 deficiency marked the first recognition of h... | UNK (FOURTEEN-DAY COURSE) | DrugDosageText | CC BY | 34603803 | 20,214,935 | 2021 |
What was the dosage of drug 'PREDNISONE'? | Very Elevated IgE, Atopy, and Severe Infection: A Genomics-Based Diagnostic Approach to a Spectrum of Diseases.
Elevated IgE has been long recognized as an important clinical marker of atopy but can be seen in a myriad of conditions. The discovery of autosomal dominant STAT3 deficiency marked the first recognition of h... | UNK (FIVE-DAY COURSE) | DrugDosageText | CC BY | 34603803 | 20,214,935 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Central nervous system fungal infection'. | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | AMPHOTERICIN B, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | AMPHOTERICIN B, VORICONAZOLE | DrugsGivenReaction | CC BY-NC-ND | 34603948 | 19,975,115 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoscytalidium infection'. | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | AMPHOTERICIN B, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Systemic mycosis'. | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | AMPHOTERICIN B, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the dosage of drug 'LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the dosage of drug 'PREDNISOLONE'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the dosage of drug 'TACROLIMUS'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the outcome of reaction 'Central nervous system fungal infection'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | Fatal | ReactionOutcome | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the outcome of reaction 'Condition aggravated'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | Fatal | ReactionOutcome | CC BY-NC-ND | 34603948 | 19,975,115 | 2021-12 |
What was the outcome of reaction 'Drug ineffective'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | Fatal | ReactionOutcome | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the outcome of reaction 'Neoscytalidium infection'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | Fatal | ReactionOutcome | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
What was the outcome of reaction 'Systemic mycosis'? | Invasive fungal infection of the brain caused by Neoscytalidium dimidiatum in a post-renal transplant patient: A case report.
Neoscytalidium is a phytopathogen that is often found in plants and soil. It mostly leads to skin and nail infections, and invasive diseases of the sinuses, lung, and brain have been described m... | Fatal | ReactionOutcome | CC BY-NC-ND | 34603948 | 19,923,914 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia.
Mucormycosis has multiple clinical phenotypes, which are more common in immunocompromised patients, especially those with diabetes mellitus. Debilitating rhino-orbital-cerebral and pulmonary infections by far represent the most typical clinical ... | AMPHOTERICIN B, DEXAMETHASONE, LOPINAVIR\RITONAVIR | DrugsGivenReaction | CC BY | 34603963 | 20,184,798 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blindness unilateral'. | Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia.
Mucormycosis has multiple clinical phenotypes, which are more common in immunocompromised patients, especially those with diabetes mellitus. Debilitating rhino-orbital-cerebral and pulmonary infections by far represent the most typical clinical ... | DEXAMETHASONE, LOPINAVIR\RITONAVIR | DrugsGivenReaction | CC BY | 34603963 | 20,156,468 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia.
Mucormycosis has multiple clinical phenotypes, which are more common in immunocompromised patients, especially those with diabetes mellitus. Debilitating rhino-orbital-cerebral and pulmonary infections by far represent the most typical clinical ... | AMPHOTERICIN B, DEXAMETHASONE, LOPINAVIR\RITONAVIR | DrugsGivenReaction | CC BY | 34603963 | 20,184,798 | 2021 |
What was the outcome of reaction 'Blindness unilateral'? | Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia.
Mucormycosis has multiple clinical phenotypes, which are more common in immunocompromised patients, especially those with diabetes mellitus. Debilitating rhino-orbital-cerebral and pulmonary infections by far represent the most typical clinical ... | Not recovered | ReactionOutcome | CC BY | 34603963 | 20,156,468 | 2021 |
What was the outcome of reaction 'Mucormycosis'? | Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia.
Mucormycosis has multiple clinical phenotypes, which are more common in immunocompromised patients, especially those with diabetes mellitus. Debilitating rhino-orbital-cerebral and pulmonary infections by far represent the most typical clinical ... | Recovered with sequelae (consequent health issues) | ReactionOutcome | CC BY | 34603963 | 20,156,468 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhoidal haemorrhage'. | Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy.
Patients on anticoagulant/antiplatelet medications are at a high risk of bleeding following external beam radiation therapy for localized prostate cancer. SBRT may reduce t... | ASPIRIN, CLOPIDOGREL BISULFATE | DrugsGivenReaction | CC BY | 34604059 | 19,991,473 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytokine release syndrome'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BASILIXIMAB, BENDAMUSTINE, CARBOPLATIN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, DOXORUBICIN, ETOPOSIDE, FLUDARABINE PHOSPHATE, GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, SINTILIMAB, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY | 34604065 | 20,208,589 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diffuse large B-cell lymphoma stage IV'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BENDAMUSTINE, CARBOPLATIN, CYCLOSPORINE, ETOPOSIDE, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, TACROLIMUS, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 34604065 | 19,971,427 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epstein-Barr virus infection'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BENDAMUSTINE, CARBOPLATIN, CYCLOSPORINE, ETOPOSIDE, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, TACROLIMUS, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 34604065 | 19,971,427 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune effector cell-associated neurotoxicity syndrome'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BASILIXIMAB, BENDAMUSTINE, CARBOPLATIN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, DOXORUBICIN, ETOPOSIDE, FLUDARABINE PHOSPHATE, GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, SINTILIMAB, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY | 34604065 | 20,208,589 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Kidney transplant rejection'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BENDAMUSTINE, CARBOPLATIN, CYCLOSPORINE, ETOPOSIDE, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, TACROLIMUS, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 34604065 | 19,971,427 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple-drug resistance'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BENDAMUSTINE, CARBOPLATIN, CYCLOSPORINE, ETOPOSIDE, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, TACROLIMUS, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 34604065 | 19,971,427 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm progression'. | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | BENDAMUSTINE, CARBOPLATIN, CYCLOSPORINE, ETOPOSIDE, IFOSFAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE SODIUM, PREDNISONE, RITUXIMAB, TACROLIMUS, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 34604065 | 19,971,427 | 2021 |
What was the administration route of drug 'CYCLOSPORINE'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Oral | DrugAdministrationRoute | CC BY | 34604065 | 19,971,427 | 2021 |
What was the administration route of drug 'GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Other | DrugAdministrationRoute | CC BY | 34604065 | 20,208,589 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34604065 | 19,971,427 | 2021 |
What was the dosage of drug 'BASILIXIMAB'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | INDUCTION OF IMMUNOSUPPRESSION THERAPY | DrugDosageText | CC BY | 34604065 | 20,208,589 | 2021 |
What was the dosage of drug 'FLUDARABINE PHOSPHATE'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | DAY -4 TO DAY -2 | DrugDosageText | CC BY | 34604065 | 20,208,589 | 2021 |
What was the dosage of drug 'GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | 2X10*6CELLS/KG | DrugDosageText | CC BY | 34604065 | 20,208,589 | 2021 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | 250 mg (milligrams). | DrugDosage | CC BY | 34604065 | 19,971,427 | 2021 |
What was the outcome of reaction 'Cytokine release syndrome'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Recovered | ReactionOutcome | CC BY | 34604065 | 20,208,589 | 2021 |
What was the outcome of reaction 'Diffuse large B-cell lymphoma stage IV'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Not recovered | ReactionOutcome | CC BY | 34604065 | 19,971,427 | 2021 |
What was the outcome of reaction 'Immune effector cell-associated neurotoxicity syndrome'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Recovered | ReactionOutcome | CC BY | 34604065 | 20,208,589 | 2021 |
What was the outcome of reaction 'Kidney transplant rejection'? | Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high... | Recovered | ReactionOutcome | CC BY | 34604065 | 19,971,427 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute graft versus host disease in skin'. | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY | 34604075 | 20,155,686 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diffuse large B-cell lymphoma stage IV'. | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34604075 | 20,147,846 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34604075 | 20,147,846 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'CISPLATIN'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 100 MG/M2, UNKNOWN | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'CYTARABINE'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 2000 MG/M2, UNKNOWN | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'DOXORUBICIN'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 50 MG/M2, UNKNOWN | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | FROM D PLUS 5, WHICH WAS TAPERED ACCORDING TO INSTITUTIONAL GUIDELINES | DrugDosageText | CC BY | 34604075 | 20,155,686 | 2021 |
What was the dosage of drug 'PREDNISOLONE'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 100 MG, UNKNOWN | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'RITUXIMAB'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 375 MG/M2 (R-CHOP AND R-DHAP) | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the dosage of drug 'VINCRISTINE'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | 1.4 MG/M2, UNKNOWN | DrugDosageText | CC BY | 34604075 | 20,147,846 | 2021 |
What was the outcome of reaction 'Acute graft versus host disease in skin'? | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric ant... | Recovered | ReactionOutcome | CC BY | 34604075 | 20,155,686 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated hypothyroidism'. | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | NIVOLUMAB | DrugsGivenReaction | CC BY | 34604086 | 19,977,173 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pemphigoid'. | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | NIVOLUMAB | DrugsGivenReaction | CC BY | 34604086 | 19,977,173 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Superinfection'. | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | NIVOLUMAB | DrugsGivenReaction | CC BY | 34604086 | 19,977,173 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vitiligo'. | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | NIVOLUMAB | DrugsGivenReaction | CC BY | 34604086 | 19,977,173 | 2021 |
What was the administration route of drug 'NIVOLUMAB'? | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34604086 | 19,977,173 | 2021 |
What was the outcome of reaction 'Immune-mediated hypothyroidism'? | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | Recovering | ReactionOutcome | CC BY | 34604086 | 19,977,173 | 2021 |
What was the outcome of reaction 'Pemphigoid'? | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | Recovering | ReactionOutcome | CC BY | 34604086 | 19,977,173 | 2021 |
What was the outcome of reaction 'Superinfection'? | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | Recovering | ReactionOutcome | CC BY | 34604086 | 19,977,173 | 2021 |
What was the outcome of reaction 'Vitiligo'? | Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.
Immunotherapy with immune checkpoint inhibitors is one of the main therapies for advanced melanoma. Nevertheless, albeit remarkable, immunotherapy results are still unsatisfactory as more than... | Recovering | ReactionOutcome | CC BY | 34604086 | 19,977,173 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis allergic'. | CNNM2-Related Disorders: Phenotype and Its Severity Were Associated With the Mode of Inheritance.
CNNM2 (Cystathionine-β-synthase-pair Domain Divalent Metal Cation Transport Mediator 2) pathogenic variants have been reported to cause hypomagnesemia, epilepsy, and intellectual disability/developmental delay (ID/DD). We ... | LACOSAMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROATE SODIUM | DrugsGivenReaction | CC BY | 34604137 | 20,576,519 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | CNNM2-Related Disorders: Phenotype and Its Severity Were Associated With the Mode of Inheritance.
CNNM2 (Cystathionine-β-synthase-pair Domain Divalent Metal Cation Transport Mediator 2) pathogenic variants have been reported to cause hypomagnesemia, epilepsy, and intellectual disability/developmental delay (ID/DD). We ... | LACOSAMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROATE SODIUM | DrugsGivenReaction | CC BY | 34604137 | 20,576,519 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | DEXAMETHASONE, ISONIAZID, LEVOFLOXACIN, LINEZOLID, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY-NC-ND | 34604547 | 20,955,815 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug level decreased'. | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | DEXAMETHASONE, ISONIAZID, LEVOFLOXACIN, LINEZOLID, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY-NC-ND | 34604547 | 20,955,815 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | ASPIRIN, DEXAMETHASONE, ISONIAZID, LEVOFLOXACIN, LINEZOLID, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY-NC-ND | 34604547 | 20,044,760 | 2021-12 |
What was the administration route of drug 'DEXAMETHASONE'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the administration route of drug 'ISONIAZID'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the administration route of drug 'LEVOFLOXACIN'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the administration route of drug 'PYRAZINAMIDE'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the administration route of drug 'RIFAMPIN'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Central nervous system vasculitis'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Confusional state'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Drug level decreased'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,955,815 | 2021-12 |
What was the outcome of reaction 'Hallucinations, mixed'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Hydrocephalus'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Paradoxical drug reaction'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
What was the outcome of reaction 'Seizure'? | A case of Clival Tuberculosis and associated meningitis.
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centre... | Recovered | ReactionOutcome | CC BY-NC-ND | 34604547 | 20,036,684 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune che... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC | 34605304 | 20,381,150 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to bone'. | Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune che... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC | 34605304 | 20,381,150 | 2021-10 |
What was the dosage of drug 'BEVACIZUMAB'? | Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune che... | TWO CYCLES | DrugDosageText | CC BY-NC | 34605304 | 20,381,150 | 2021-10 |
What was the dosage of drug 'CARBOPLATIN'? | Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune che... | TWO CYCLES | DrugDosageText | CC BY-NC | 34605304 | 20,381,150 | 2021-10 |
What was the dosage of drug 'PEMETREXED'? | Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune che... | TWO CYCLES | DrugDosageText | CC BY-NC | 34605304 | 20,381,150 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
KRAS is mutated in ∼30% of non-small-cell lung cancer (NSCLC) but it has also been identified as one of the mechanisms underlying resistance to tyrosine ... | ERLOTINIB | DrugsGivenReaction | CC BY-NC-ND | 34607284 | 20,415,268 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple organ dysfunction syndrome'. | Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
Human lives and nations' economies have been adversely affected worldwide by the COVID-19 pandemic. The hyperinflammatory state associated with the disease may be related to mortality. Systemic glucocorticoid is the first-line therapy for ... | APIXABAN, AZITHROMYCIN, METHYLPREDNISOLONE, PREDNISOLONE, TOFACITINIB | DrugsGivenReaction | CC BY | 34607309 | 20,349,797 | 2021-10-04 |
What was the administration route of drug 'ENOXAPARIN'? | Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
Human lives and nations' economies have been adversely affected worldwide by the COVID-19 pandemic. The hyperinflammatory state associated with the disease may be related to mortality. Systemic glucocorticoid is the first-line therapy for ... | Subcutaneous | DrugAdministrationRoute | CC BY | 34607309 | 20,368,204 | 2021-10-04 |
What was the administration route of drug 'TOFACITINIB'? | Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
Human lives and nations' economies have been adversely affected worldwide by the COVID-19 pandemic. The hyperinflammatory state associated with the disease may be related to mortality. Systemic glucocorticoid is the first-line therapy for ... | Oral | DrugAdministrationRoute | CC BY | 34607309 | 20,368,204 | 2021-10-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arrhythmia'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrial fibrillation'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrioventricular block'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac arrest'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocarditis'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pericardial disease'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sinus node dysfunction'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular arrhythmia'. | Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated w... | ATEZOLIZUMAB | DrugsGivenReaction | CC BY-NC | 34607896 | 20,039,607 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adrenalitis'. | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sp... | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IPILIMUMAB, NIVOLUMAB, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC | 34607899 | 20,020,114 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholangiocarcinoma'. | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sp... | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IPILIMUMAB, NIVOLUMAB, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC | 34607899 | 20,020,114 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sp... | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IPILIMUMAB, NIVOLUMAB, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC | 34607899 | 20,020,114 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colon cancer'. | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sp... | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IPILIMUMAB, NIVOLUMAB, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC | 34607899 | 20,020,114 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sp... | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IPILIMUMAB, NIVOLUMAB, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC | 34607899 | 20,020,114 | 2021-10 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.